Overview

Enzastaurin for Patients With Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company